glp 1 blue cross blue shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss Blue Cross Blue Shield

doi: 10.1056/NEJM197902153000726 212 HerbertVGardnerAColmanN

The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms. An estimated 1.6 million UK adults used GLP-1s such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) to lose weight between early 2024 and early 2025, with an additional 3.3 million interested in using weight loss drugs during 2026

clinical effect sizes vary by indication, dosing, individual factors, and adherence

Free Hair & Skin Assessment by the experts in the industry